Détection et diagnostic des exosomes
| Exosome Analytics develops innovative technics for highly sensitive profiling of histological markers on exosomes that allows their application in the diagnosis of different pathologies | ||
| Compétences recherchées :Missions: • Responsibility for Business development and operational activity of the company • Strategy development Short term priorities: Launching the RUO products (commercialization, regulatory filings, participation in clients acquisition, etc) Long term priorities: Clinical validation of diagnostic platforms for early screening of ovarian and prostate cancers (Medical Device Clinical Trials) for FDA/EMA certification Candidate profile: - You are a qualified and enthusiastic person, you must be ready to invest your time and knowledge in the operational development of the startup - You have a credible experience within a medtech or bitech start-up (operations/business development) or within a commercial department of a healthcare company. - You are very familiar with the healthcare business ecosystem (overall value chain, from R&D and labs to final patient & investors) Availability: ASAP | Recherche :
|
| |
| Nombre de personne(s) dans le projet : 2 |
Elena
 |
| Profil de l’équipe et apports :
Master in physics, PhD in molecular biology, the founder of Exosome Analytics worked for 20+ years (10 years in research of exosomes) in public and private research centers in France, Germany and the United States (ENS ULM, the Max Planck Institute, Argonne National Laboratory and others). Financial activity of the company is assured by an expert in fundraising. The Scientific Council is made up of experts in exosome research and oncologists |
| Description détaillée du projet : Exosome Analytics is a quickly growing Company with very high technical expertise in exosome research and liquid biopsy tests. The company has developed brand new solutions for highly sensitive analysis of histological markers on exosomes. Based on these techniques, very promising results for early screening and profiling of ovarian and prostate tumors were obtained, and now needs to commercialize the first products, and organize clinical trials to evaluate exosome-based platform for early screening of urogenital cancers. Several patents are being finalized, the results are published in high IF scientific journals (ex: https://doi.org/10.3389/fcell.2023.1057484) and a number of prospective clients are already interested in the scalable RUO products. Collaboration with public and private companies is established. Exosome Analytics is supported by Genopole incubator and accelerator WILCO. Context: The expected market growth of exosome-related technologies and liquid biopsy over the next 5-10y is huge ( The size is expected to reach 660 M€ for exosome research market and 7B€ for liquid biopsy market). Currently, very few competitors are present on the market. The market essentially depends on the development of new technologies and to date there are very few products (if any) allowing the detection of histological markers on pathological exosomes |
| Les points forts du projet : The kits developed by Exosome Analytics are of a higher sensitivity than that currently available kits from the competitors. This makes it possible to analyze very small quantities of pathological markers on exosomes and improve the accuracy of diagnosis of different diseases including cancer. Collaboration with certain public laboratories for the development of an innovative cancer diagnostic platform has been established. |
Question ou commentaire public
